{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:45:21Z","timestamp":1773294321503,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00120-026-02765-z","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:40:47Z","timestamp":1769596847000},"page":"271-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Von ungezielt zu Pr\u00e4zisionsonkologie: Pr\u00e4diktive Biomarker und Target-Therapien beim fortgeschrittenen Urothelkarzinom","From nontargeted to precision oncology: predictive biomarkers and targeted therapies in advanced urothelial carcinoma"],"prefix":"10.1007","volume":"65","author":[{"given":"G\u00fcnter","family":"Niegisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Kl\u00fcmper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2765_CR1","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky\u00a0MD, Hahn\u00a0NM, Rosenberg\u00a0J et\u00a0al (2011) Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy. J\u00a0Clin Oncol 29:2432\u20132438. https:\/\/doi.org\/10.1200\/JCO.2011.34.8433","journal-title":"J Clin Oncol"},{"key":"2765_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00120-022-01760-4","volume":"61","author":"G Niegisch","year":"2022","unstructured":"Niegisch\u00a0G, von Amsberg\u00a0G, Rehlinghaus\u00a0M et\u00a0al (2022) Metastatic urothelial carcinoma-guideline-based therapy and new options. Urologie 61:265\u2013272. https:\/\/doi.org\/10.1007\/s00120-022-01760-4","journal-title":"Urologe A"},{"key":"2765_CR3","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Klumper","year":"2024","unstructured":"Klumper\u00a0N, Tran\u00a0NK, Zschabitz\u00a0S et\u00a0al (2024) NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J\u00a0Clin Oncol 42:2446\u20132455. https:\/\/doi.org\/10.1200\/JCO.23.01983","journal-title":"J Clin Oncol"},{"key":"2765_CR4","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot\u00a0Y, Matsubara\u00a0N, Park\u00a0SH et\u00a0al (2023) Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 389:1961\u20131971. https:\/\/doi.org\/10.1056\/NEJMoa2308849","journal-title":"N Engl J Med"},{"key":"2765_CR5","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin\u00a0DF, Witjes\u00a0JA, Gschwend\u00a0JE et\u00a0al (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 384:2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"},{"key":"2765_CR6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden\u00a0MS, Sonpavde\u00a0G, Powles\u00a0T et\u00a0al (2023) Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med 389:1778\u20131789. https:\/\/doi.org\/10.1056\/NEJMoa2309863","journal-title":"N Engl J Med"},{"key":"2765_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar\u00a0AV, Galsky\u00a0MD, Rosenberg\u00a0JE et\u00a0al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389:67\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(16)32455-2","journal-title":"Lancet"},{"key":"2765_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt\u00a0J, de Wit\u00a0R, Vaughn\u00a0DJ et\u00a0al (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 376:1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"2765_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles\u00a0T, Duran\u00a0I, van der Heijden\u00a0MS et\u00a0al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a\u00a0multicentre, open-label, phase\u00a03 randomised controlled trial. Lancet 391:748\u2013757. https:\/\/doi.org\/10.1016\/S0140-6736(17)33297-X","journal-title":"Lancet"},{"key":"2765_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky\u00a0MD, Arija\u00a0JAA, Bamias\u00a0A et\u00a0al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395:1547\u20131557. https:\/\/doi.org\/10.1016\/S0140-6736(20)30230-0","journal-title":"Lancet"},{"key":"2765_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T, Csoszi\u00a0T, Ozguroglu\u00a0M et\u00a0al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22:931\u2013945. https:\/\/doi.org\/10.1016\/S1470-2045(21)00152-2","journal-title":"Lancet Oncol"},{"key":"2765_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo\u00a0AB, Ballman\u00a0KV, Sonpavde\u00a0G et\u00a0al (2025) Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 392:45\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2401726","journal-title":"N Engl J Med"},{"key":"2765_CR13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Catto\u00a0JWF, Galsky\u00a0MD et\u00a0al (2024) Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med 391:1773\u20131786. https:\/\/doi.org\/10.1056\/NEJMoa2408154","journal-title":"N Engl J Med"},{"key":"2765_CR14","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","volume":"393","author":"T Powles","year":"2025","unstructured":"Powles\u00a0T, Kann\u00a0AG, Castellano\u00a0D et\u00a0al (2025) ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med 393:2395\u20132408. https:\/\/doi.org\/10.1056\/NEJMoa2511885","journal-title":"N Engl J Med"},{"key":"2765_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T, Assaf\u00a0ZJ, Davarpanah\u00a0N et\u00a0al (2021) ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nat Cell Biol 595:432\u2013437. https:\/\/doi.org\/10.1038\/s41586-021-03642-9","journal-title":"Nature"},{"key":"2765_CR16","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","volume":"29","author":"SV Lindskrog","year":"2023","unstructured":"Lindskrog\u00a0SV, Birkenkamp-Demtroder\u00a0K, Nordentoft\u00a0I et\u00a0al (2023) Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. Clin Cancer Res 29:4797\u20134807. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1860","journal-title":"Clin Cancer Res"},{"key":"2765_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.eururo.2022.10.020","volume":"83","author":"F Erlmeier","year":"2023","unstructured":"Erlmeier\u00a0F, Klumper\u00a0N, Landgraf\u00a0L et\u00a0al (2023) Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. Eur Urol Oncol 83:133\u2013142. https:\/\/doi.org\/10.1016\/j.eururo.2022.10.020","journal-title":"Eur Urol"},{"key":"2765_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejca.2018.11.007","volume":"106","author":"M Eckstein","year":"2019","unstructured":"Eckstein\u00a0M, Erben\u00a0P, Kriegmair\u00a0MC et\u00a0al (2019) Performance of the Food and Drug Administration\/EMA-approved programmed cell death ligand\u20111 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer 106:234\u2013243. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.007","journal-title":"Eur J Cancer"},{"key":"2765_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1159\/000527879","volume":"107","author":"C Bolenz","year":"2023","unstructured":"Bolenz\u00a0C, Kunath\u00a0F, Zengerling\u00a0F et\u00a0al (2023) Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma: Systematic Review of International Clinical Trials. Urol Int 107:480\u2013488. https:\/\/doi.org\/10.1159\/000527879","journal-title":"Urol Int"},{"key":"2765_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles\u00a0T, Eder\u00a0JP, Fine\u00a0GD et\u00a0al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558\u2013562. https:\/\/doi.org\/10.1038\/nature13904","journal-title":"Nature"},{"key":"2765_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Valderrama\u00a0BP, Gupta\u00a0S et\u00a0al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 390:875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"2765_CR22","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng\u00a0X, Zeng\u00a0G, Zhang\u00a0C et\u00a0al (2025) Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. N Engl J Med 393:2324\u20132337. https:\/\/doi.org\/10.1056\/NEJMoa2511648","journal-title":"N Engl J Med"},{"key":"2765_CR23","doi-asserted-by":"crossref","unstructured":"Vulsteke C, Kaimakliotis H, Danchaivijitr P et\u00a0al. Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase\u00a0III KEYNOTE-905 study. ESMO 2025; September 2025 2025; Berlin.","DOI":"10.1016\/j.annonc.2025.09.124"},{"key":"2765_CR24","unstructured":"Anonym (2025) KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery. https:\/\/www.merck.com\/news\/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-significantly-improved-event-free-survival-overall-survival-and-pathologic-complete-response-rates-for-cisplatin-eligible-pa\/"},{"key":"2765_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","volume":"35","author":"Y Loriot","year":"2024","unstructured":"Loriot\u00a0Y, Petrylak\u00a0DP, Rezazadeh Kalebasty\u00a0K et\u00a0al (2024) TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Ann Oncol 35:392\u2013401. https:\/\/doi.org\/10.1016\/j.annonc.2024.01.002","journal-title":"Ann Oncol"},{"key":"2765_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam\u00a0F, Makker\u00a0V, Oaknin\u00a0A et\u00a0al (2024) Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J\u00a0Clin Oncol 42:47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005","journal-title":"J Clin Oncol"},{"key":"2765_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100637","volume":"6","author":"X Yan","year":"2025","unstructured":"Yan\u00a0X, Li\u00a0J, Xu\u00a0H et\u00a0al (2025) Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study. Med 6:100637. https:\/\/doi.org\/10.1016\/j.medj.2025.100637","journal-title":"Med"},{"key":"2765_CR28","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg\u00a0J, Sridhar\u00a0SS, Zhang\u00a0J et\u00a0al (2020) EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J\u00a0Clin Oncol 38:1041\u20131049. https:\/\/doi.org\/10.1200\/JCO.19.02044","journal-title":"J Clin Oncol"},{"key":"2765_CR29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T, Rosenberg\u00a0JE, Sonpavde\u00a0GP et\u00a0al (2021) Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 384:1125\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa2035807","journal-title":"N Engl J Med"},{"key":"2765_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/his.15130","volume":"84","author":"V Bahlinger","year":"2024","unstructured":"Bahlinger\u00a0V, Branz\u00a0A, Strissel\u00a0PL et\u00a0al (2024) Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN\u20114 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. Histopathology 84:863\u2013876. https:\/\/doi.org\/10.1111\/his.15130","journal-title":"Histopathology"},{"key":"2765_CR31","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu\u00a0CE, Sjostrom\u00a0M, Egusa\u00a0EA et\u00a0al (2021) Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res 27:5123\u20135130. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4175","journal-title":"Clin Cancer Res"},{"key":"2765_CR32","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid\u00a0PM, Satpayev\u00a0D, Yang\u00a0P et\u00a0al (2016) Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin\u20114 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 76:3003\u20133013. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313","journal-title":"Cancer Res"},{"key":"2765_CR33","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","volume":"29","author":"N Klumper","year":"2023","unstructured":"Klumper\u00a0N, Ralser\u00a0DJ, Ellinger\u00a0J et\u00a0al (2023) Membranous NECTIN\u20114 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res 29:1496\u20131505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1764","journal-title":"Clin Cancer Res"},{"key":"2765_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00951-2","author":"N Klumper","year":"2024","unstructured":"Klumper\u00a0N, Cox\u00a0A, Sjodahl\u00a0G et\u00a0al (2024) Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer. Nat Rev Urol. https:\/\/doi.org\/10.1038\/s41585-024-00951-2","journal-title":"Nat Rev Urol"},{"key":"2765_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.euf.2024.04.001","volume":"10","author":"N Klumper","year":"2024","unstructured":"Klumper\u00a0N, Eckstein\u00a0M (2024) Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer. Eur Urol Oncol 10:224\u2013226. https:\/\/doi.org\/10.1016\/j.euf.2024.04.001","journal-title":"Eur Urol Focus"},{"key":"2765_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles\u00a0MA, Hurst\u00a0CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15:25\u201341. https:\/\/doi.org\/10.1038\/nrc3817","journal-title":"Nat Rev Cancer"},{"key":"2765_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111859","volume":"41","author":"TN Clinton","year":"2022","unstructured":"Clinton\u00a0TN, Chen\u00a0Z, Wise\u00a0H et\u00a0al (2022) Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep Med 41:111859. https:\/\/doi.org\/10.1016\/j.celrep.2022.111859","journal-title":"Cell Rep"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02765-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02765-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02765-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:50:32Z","timestamp":1773233432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02765-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2765"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02765-z","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Eckstein: speaker\u02bcs honoraria: Eisai, AstraZeneca, MSD, Roche, Astellas, Janssen-Cilag, Diaceutics, Cepheid; advisory role for: AstraZeneca, MSD, Janssen-Cilag, Diaceutics, GenomicHealth, Owkin, Merck, Pfizer; personal fees and travel costs: AstraZeneca, MSD, Roche, Astellas, Janssen-Cilag, Diaceutics, GenomicHealth, Cepheid; research funding: AstraZeneca, MedImmune, Janssen-Cilag, Stratifyer, Cepheid, Owkin, Gilead, QuIP GmbH. S.\u00a0Zsch\u00e4bitz: advisory board\/honoraria (institutional and\/or personal): Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, EUSA, Gilead, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, Roche, SanofiAventis, StreamedUp, Urotrials, Urotube,  Zentiva; Forschungsf\u00f6rderung: Eisai; Studienfinanzierung: Amgen, AstraZeneca, AVEO, Bayer, Biontech, Bristol-Myers Squibb, Calithera, Exelixis, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen\/Astellas, Urotrials,Reisekosten und Fortbildungskosten: Amgen, Astellas, AstraZeneca,Bayer, EISAI, Ipsen, Johnson & Johnson, Merck, MSD, Pfizer. G.\u00a0Niegisch: Vortragst\u00e4tigkeit: Roche, MEDAC, Pfizer, BMS, AstraZeneca, Astellas, Merck, medac, MSD, Johnson & Johnson, urotube, solution-Akademie, StreamedUp; beratende Funktion\/Advisory Board: Roche Pharma, BMS, Merck, Pfizer, Ipsen, Johnson & Johnson, AstraZeneca, Astellas. Reisekostenzusch\u00fcsse, Kongressregistrierungen: Roche Pharma, Pfizer, Merck, AstraZeneca, Johnson & Johnson, Ipsen. N.\u00a0Kl\u00fcmper: stock and other ownership interests: Bicycle Therapeutics Plc.; honoraria, personal fees\/speaker\u2019s honoraria: Astellas, Novartis, Ipsen, Photocure, MSD, Merck; consulting or advisory role: Astellas, Eisai, Merck, MSD, Bicycle Therapeutics Plc (clinical advisory board member); research funding: Bicycle Therapeutics Plc.; travel, accommodations, expenses: Astellas, Novartis, Ipsen, Photocure, MSD, Merck, Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}